COSMIC 313: Efficacy Data

Hyung Kim, MD, discussed the PROBE trial, a trial in progress, for patients with advanced kidney cancer.

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

Atezolizumab plus cabozantinib or cabozantinib alone showed efficacy and manageable safety in second-line renal cell carcinoma.

During a live event, Chandler H. Park, MD, and event participants looked at quality of life, tolerability, and rechallenging in second-line RCC therapy.